Objectives To compare clinical outcomes between patients with locally advanced
(unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract …

Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in
metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials …

Background Advanced upper tract urothelial carcinoma (UTUC) has different molecular and
genetic features from the commonest carcinoma of the bladder, suggesting a possible …

Background/Aim: Immune checkpoint inhibitors (ICI) have become important tools for the
treatment of advanced urothelial carcinoma (aUC). However, the clinical strategy using ICIs …

Purpose The application of platinum-based chemotherapeutic agents is the traditional
treatment paradigm for advanced and metastatic urothelial carcinoma, which has changed …

Abstract Context Immune checkpoint inhibitors (ICIs) are widely used in the management of
patients with advanced urothelial carcinoma (aUC). However, its performance in aUC …

Background Immune checkpoint inhibitors (ICIs) represent an appealing treatment for
patients with advanced urothelial cancer (aUC) and a poor performance status (PS) …

Background Recent studies suggest improvements in response to salvage chemotherapy
(CT) after immune checkpoint inhibitors (ICIs) in several types of cancer. Our objective was …

Objectives: To examine patient and disease characteristics, toxicity, and clinical outcomes
for patients with advanced urothelial carcinoma (aUC) who are rechallenged with immune …

Background Combinations of immune checkpoint inhibitors (ICI) with platinum-based
chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with …